Stocks News

LAST PRICE
39.8800
TODAY'S CHANGE (%)
Trending Down-0.4300 (-1.0667%)

Bid / Lots
35.0000/ 1
Ask / Lots
63.6400/ 2
Open / Previous Close
40.4800 / 40.3100
Day Range
Low 39.0100
High 41.2600
52 Week Range
Low 27.9850
High 50.9900
Volume
362,875
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Apr 16, 2024
- Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting, from 8:30AM ET on Tuesday Apr 16, 2024 by GlobeNewswire
  8:30AM ET on Tuesday Apr 16, 2024 by GlobeNewswire
  Companies Mentioned: XENE
- Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting, from 8:30AM ET on Tuesday Apr 16, 2024 by Dow Jones
  8:30AM ET on Tuesday Apr 16, 2024 by Dow Jones
  Companies Mentioned: XENE
  
  Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
  
  VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced two oral presentations highlighting XEN1101 clinical data at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver, CO.
Apr 12, 2024
- DJ Xenon Pharmaceuticals Price Target Maintained With a $62.00/Share by Needham, from 7:13AM ET on Friday Apr 12, 2024 by Dow Jones
  7:13AM ET on Friday Apr 12, 2024 by Dow Jones
  Companies Mentioned: XENE
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/XENE/analyst-ratings
  
  (END) Dow Jones Newswires
  
  April 12, 2024 07:13 ET (11:13 GMT)
Apr 10, 2024
- DJ Xenon Pharmaceuticals Price Target Maintained With a $65.00/Share by Cantor Fitzgerald, from 9:57AM ET on Wednesday Apr 10, 2024 by Dow Jones
  9:57AM ET on Wednesday Apr 10, 2024 by Dow Jones
  Companies Mentioned: XENE
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/XENE/analyst-ratings
  
  (END) Dow Jones Newswires
  
  April 10, 2024 09:57 ET (13:57 GMT)
- Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference, from 8:30AM ET on Wednesday Apr 10, 2024 by GlobeNewswire
  8:30AM ET on Wednesday Apr 10, 2024 by GlobeNewswire
  Companies Mentioned: XENE

Today
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4), from 2 hours ago by GlobeNewswire
  2 hours ago by GlobeNewswire
  Companies Mentioned: IOVA
Yesterday
- SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024, from 7:00AM ET on Thursday Apr 18, 2024 by GlobeNewswire
  7:00AM ET on Thursday Apr 18, 2024 by GlobeNewswire
  Companies Mentioned: SWTX
Mar 22, 2024
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4), from 5:30PM ET on Friday Mar 22, 2024 by GlobeNewswire
  5:30PM ET on Friday Mar 22, 2024 by GlobeNewswire
  Companies Mentioned: IOVA
Mar 19, 2024
- Thinking about buying stock in SoundHound AI, Intuitive Machines, Iovance Biotherapeutics, Silence Therapeutics, or Altimmune?, from 9:31AM ET on Tuesday Mar 19, 2024 by PR Newswire
  9:31AM ET on Tuesday Mar 19, 2024 by PR Newswire
  Companies Mentioned: IOVA, ALT, SLN, LUNR, SOUN
Mar 14, 2024
- Kuehn Law Encourages Investors of SpringWorks, Therapeutics Inc. to Contact Law Firm, from 1:53PM ET on Thursday Mar 14, 2024 by Newsfile
  1:53PM ET on Thursday Mar 14, 2024 by Newsfile
  Companies Mentioned: SWTX
- Piper Sandler Adjusts Iovance Biotherapeutics Price Target to $19 From $18, Maintains Overweight Rating, from 10:50AM ET on Thursday Mar 14, 2024 by MT Newswires
  10:50AM ET on Thursday Mar 14, 2024 by MT Newswires
  Companies Mentioned: IOVA
Mar 12, 2024
- Apogee Closes $483 million Upsized Stock Offering, from 4:39PM ET on Tuesday Mar 12, 2024 by MT Newswires
  4:39PM ET on Tuesday Mar 12, 2024 by MT Newswires
  Companies Mentioned: APGE
- Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 Million, from 4:01PM ET on Tuesday Mar 12, 2024 by GlobeNewswire
  4:01PM ET on Tuesday Mar 12, 2024 by GlobeNewswire
  Companies Mentioned: APGE
Mar 8, 2024
- Apogee Therapeutics Prices Upsized $420 Million Share Offering, from 5:14AM ET on Friday Mar 08, 2024 by MT Newswires
  5:14AM ET on Friday Mar 08, 2024 by MT Newswires
  Companies Mentioned: APGE
Mar 7, 2024
- Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering, from 6:50PM ET on Thursday Mar 07, 2024 by GlobeNewswire
  6:50PM ET on Thursday Mar 07, 2024 by GlobeNewswire
  Companies Mentioned: APGE

Xenon Pharmaceuticals Inc
NASDAQ:XENEUnited States

Search Criteria

Apr 16, 2024

Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting, from 8:30AM ET on Tuesday Apr 16, 2024 by GlobeNewswire

Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting, from 8:30AM ET on Tuesday Apr 16, 2024 by Dow Jones

Apr 12, 2024

DJ Xenon Pharmaceuticals Price Target Maintained With a $62.00/Share by Needham, from 7:13AM ET on Friday Apr 12, 2024 by Dow Jones

Apr 10, 2024

DJ Xenon Pharmaceuticals Price Target Maintained With a $65.00/Share by Cantor Fitzgerald, from 9:57AM ET on Wednesday Apr 10, 2024 by Dow Jones

Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference, from 8:30AM ET on Wednesday Apr 10, 2024 by GlobeNewswire

Peers Headlines

Today

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4), from 2 hours ago by GlobeNewswire

Yesterday

SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024, from 7:00AM ET on Thursday Apr 18, 2024 by GlobeNewswire

Mar 22, 2024

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4), from 5:30PM ET on Friday Mar 22, 2024 by GlobeNewswire

Mar 19, 2024

Thinking about buying stock in SoundHound AI, Intuitive Machines, Iovance Biotherapeutics, Silence Therapeutics, or Altimmune?, from 9:31AM ET on Tuesday Mar 19, 2024 by PR Newswire

Mar 14, 2024

Kuehn Law Encourages Investors of SpringWorks, Therapeutics Inc. to Contact Law Firm, from 1:53PM ET on Thursday Mar 14, 2024 by Newsfile

Piper Sandler Adjusts Iovance Biotherapeutics Price Target to $19 From $18, Maintains Overweight Rating, from 10:50AM ET on Thursday Mar 14, 2024 by MT Newswires

Mar 12, 2024

Apogee Closes $483 million Upsized Stock Offering, from 4:39PM ET on Tuesday Mar 12, 2024 by MT Newswires

Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 Million, from 4:01PM ET on Tuesday Mar 12, 2024 by GlobeNewswire

Mar 8, 2024

Apogee Therapeutics Prices Upsized $420 Million Share Offering, from 5:14AM ET on Friday Mar 08, 2024 by MT Newswires

Mar 7, 2024

Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering, from 6:50PM ET on Thursday Mar 07, 2024 by GlobeNewswire